Image description

MAVERIC Trial of the ARTO System Encompasses Four Continents and 15 Centres of Excellence

The MAVERIC (MitrAl ValvE RepaIr Clinical) trial program is a prospective, single arm group of studies evaluating the safety and performance of the ARTO System in patients with congestive heart failure associated with mitral regurgitation.

"The ARTO System is a unique solution to treating FMR. The device is safe, the procedure is simple, and the benefit to the patient is almost immediate."

- Simon Redwood, MB, BS, MD, Honorary Consultant Cardiologist and Professor of Interventional Cardiology, St Thomas' Hospital, London, UK

MAVERIC Trial Design

Primary Endpoint

  1. Major Adverse Event rate* to 30 days
  2. Reduction of > 1 MR Grade mitral regurgitation at 30 days
  3. Acute Technical Success (MVARC Definition)
* death, stroke, MI, cardiac tamponade, device-related cardiac surgery, and renal failure.

Secondary Outcome Measures

  1. MAE Rate & MR reduction at 6 Months, 1, 2 and 3 years
  2. NYHA Class
  3. Six Minute Walk Test
  4. Quality of Life

Key Inclusion Criteria

  1. Refused for MV surgery
  2. NYHA Class II-IV of any etiology
  3. Symptomatic with MR grade ≥ 2+


Immediate and Long-Term Maintained Results

31 patients enrolled in the MAVERIC Trial provide evidence that treatment with the ARTO System results in meaningful, immediate and long term MR reduction.

tab photo

"Ten years ago, I had a heart attack and was treated with a stent. When my condition worsened, I was offered this operation, which made me feel much better. These days, I exercise with my hunting dog: I cycle and he follows me. He is very strong, so have to keep up. And I do!"

- E.L., MAVERIC Trial patient, Latvia